A UK trial for the investigation of stable chest pain: can we improve patient experience, outcomes and NHS cost-efficiency compared to the current NICE guidelines?

| Submission date 19/01/2022 | Recruitment status No longer recruiting | [X] Prospectively registered [X] Protocol | | |
|-------------------------------|---|--|--|--|
| Registration date | Overall study status | Statistical analysis plan | | |
| Last Edited | | Results Individual participant data | | |
| 28/07/2025 Cire | Circulatory System | [X] Record updated in last year | | |

Plain English summary of protocol

Background and study aims

Coronary artery disease (narrowing of the heart arteries) is the typical cause of angina (cardiac chest pain) and is becoming more common as people live longer with multiple heart disease risk factors (e.g. diabetes, smoking, high blood pressure, and high cholesterol). In the UK, about 2 million people have angina and about 200,000 are referred to hospital each year for further investigation. There are lots of different tests to investigate suspected angina, but doctors have different opinions as to the best approach, and international guidelines make very different recommendations. This leads to wide practice variation, inefficiency of healthcare resources and it may adversely impact on patient experience and outcomes. What most doctors agree on is that we do too many invasive X-ray angiograms. About 60% of angiograms performed do not find significant narrowing of the heart arteries, and as such, do not lead to a direct change in management for that patient.

Recent UK NICE guidelines recommend a non-invasive CT angiogram as the first-line test for all patients with suspected angina. This one-size-fits-all approach does not recognise individual patient characteristics, risk factors or likelihood of them having disease. Whilst cardiac CT is an excellent test to exclude narrowing of the heart arteries when they are normal, it can lead to over-estimation of severity when moderate disease is present. It has been suggested that this approach may lead to further increases in the rates of invasive angiography, more additional downstream investigations and increased NHS costs, with no difference in patient outcomes. In addition, the recent UK NICE guidelines if fully adopted would require major service reorganisation in every hospital, and large capital and revenue investment to accommodate the 700% predicted increase in cardiac CT capacity. Thus many doctors believe that this major NHS service reorganisation should first be robustly evaluated in the setting of a clinical trial to demonstrate that it is both appropriate and cost-efficient.

The aim of this study is to try to improve the investigation and management of patients with suspected cardiac chest pain (angina), both in terms of NHS resource use and also patient experience and outcomes; producing results that would be highly generalisable across the NHS.

Who can participate?

Males aged 45 years and over and females aged 50 years and over with atypical or typical angina and at least one major cardiac risk factor (diabetes, peripheral arterial disease, cerebrovascular disease, current or past tobacco use, high blood pressure, dyslipidaemia or a family history of premature coronary artery disease) referred to NHS cardiology outpatient services, requiring further investigation according to NICE CG95 guidelines, and who are deemed suitable for coronary revascularisation if required.

What does the study involve?

Patients will have either a computerised tomography cardioangiogram (a CT scan of the heart), a cardiac MRI scan, a stress echocardiogram (an ultrasound scan of the heart) or a nuclear perfusion scan of the heart with single-photon emission computerised tomography (MPS-SPECT), depending on which group they are randomly allocated to and their calculated risk of having heart disease. Patients will also complete three questionnaires at the start of the study and after 6 and 12 months.

What are the possible benefits and risks of participating?

All of the study procedures are part of routine clinical care and no additional procedures will be undertaken. Participants may be less likely to have unnecessary tests. Patients will also have more contact with the clinical care team and have more opportunities to ask questions and be informed about their health, which some patients find helpful.

Where is the study run from? University of Leeds and Leeds Clinical Trials Research Unit (UK)

When is the study starting and how long is it expected to run for? May 2019 to April 2027

Who is funding the study? 1. Heart Research UK 2. British Heart Foundation (UK) (quality of life sub-study)

Who is the main contact? Dr Laura Jones L.M.Jones@Leeds.ac.uk

Contact information

Type(s) Principal Investigator

Contact name Prof John Greenwood

ORCID ID https://orcid.org/0000-0002-2861-0914

Contact details Division of Biomedical Imaging LIGHT Building Clarendon Way Leeds United Kingdom LS2 9JT +44 (0)113 343 8469 J.Greenwood@Leeds.ac.uk

Type(s) Principal Investigator

Contact name Dr Peter Swoboda

ORCID ID https://orcid.org/0000-0001-7162-7079

Contact details

Division of Biomedical Imaging LIGHT Building Clarendon Way Leeds United Kingdom LS2 9JT +44 (0)113 39 28206 P.Swoboda@Leeds.ac.uk

Type(s)

Public

Contact name Dr Laura Jones

Contact details Leeds Institute of Cardiovascular and Metabolic Medicine University of Leeds Leeds United Kingdom LS2 9JT +44 (0)7921121815 L.M.jones@Leeds.ac.uk

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number 302218

ClinicalTrials.gov number Nil known

Secondary identifying numbers

CPMS 50598, IRAS 302218

Study information

Scientific Title

A pragmatic approach to the investigation of stable chest pain: a UK, multi-centre, randomised trial to improve patient experience, outcomes and NHS cost efficiency

Acronym

CE-MARC 3

Study objectives

The primary question is: 'can we improve the management of patients with new-onset chest pain, both from a patient perspective and an NHS (payer) perspective?'

The proposed trial will address this by answering the following: compared to the current UK NICE guidelines, can a more pragmatic diagnostic pathway to guide the management of patients with suspected cardiac chest pain, result in a) lower rates of invasive angiography without evidence of obstructive disease, b) less downstream resource utilisation and c) improved patient experience and outcomes.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 01/10/2021, London Bridge Research Ethics Committee (postal address: not available; +44 (0)207 1048202; +44 (0)207 1048124; londonbridge.rec@hra.nhs.uk), REC ref: 21/LO/0666

Study design

Randomized; Both; Design type: Diagnosis, Imaging, Validation of investigation /therapeutic procedures

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Diagnostic

Participant information sheet See study outputs table

Health condition(s) or problem(s) studied Stable chest pain

Interventions

People who come to the hospital outpatients department with stable new-onset chest pain or those that have been admitted to cardiology wards will be approached to take part in the trial. If they take part they will be in one of the two arms of the trial and this will be randomly decided (by a computer). The two strategies for the first-line test are:

1. Usual care following the NICE guidelines (this essentially means having a non-invasive CT coronary angiography (CTCA), anatomical test)

2. Pragmatic care following the European Society of Cardiology (ESC) 2019 guidelines whereby a patient could get either a) an MRI scan of the heart (functional test), b) a stress echocardiogram (ultrasound scan) of the heart (functional test), c) a nuclear perfusion scan of the heart (functional test), d) a non-invasive CTCA with added computer calculations (fractional flow reserve [FFR]-CT, anatomical test) which is no different for the patient than having a CTCA. The choice of the first test in this arm would be by shared decision making between the patient and the doctor (cardiologist) guided by contemporary risk stratification determined by the doctor. There will be no extra visits but patients may be asked to complete three short (optional) questionnaires that ask about their health and well-being at baseline, 6 and 12 months. The questionnaires are validated and are expected to take no longer than 20 minutes to complete in total (at each time point). They can be completed during hospital visits or submitted electronically via the Clinical Trials Research portal (the link will be sent out via email or SMS).

In either arm, if the first test is abnormal patients may be asked to go for an invasive angiogram (this would also be the case if a patient was not in the trial). If the first test is normal then NICE guideline-directed medical therapy would be recommended by the doctor. If the first test is inconclusive then the patient could have second-line non-invasive testing or invasive angiography, based upon shared decision-making and in line with current UK NICE guidelines.

The researchers will collect all the test results to see how many of the invasive angiograms were abnormal in each of the trial arms (and how many were normal - i.e. how many showed no evidence of significant disease). They will analyse questionnaire results completed at baseline, 6 and 12 months, and will review medical records at the same intervals.

Patients will also be followed up for up to 10 years to see if they have any further downstream tests, and if they have any health problems like a heart attack (thankfully only very few people have).

Setting: Secondary care cardiology departments that have well-established clinical NHS services for both anatomical and functional cardiac imaging. Initially nine high volume, experienced research centres that are geographically spread and with ethnically diverse populations have been selected (Leeds, Glasgow, Leicester, Bristol, Oxford, Barts (London), Liverpool, Wakefield and Southampton); other centres could join based on their clinical services and trial experience.

Intervention Type

Other

Primary outcome measure

Time to composite endpoint of cardiovascular death, myocardial infarction, unobstructive coronary artery disease (CAD) at invasive angiography, defined as the invasive reference standard FFR measurement of >0.80 (or instantaneous wave-free ratio [iFR] ≥0.90), i.e. no functional ischaemia, at the time of coronary angiography (or no coronary stenosis >70% on quantitative coronary angiography should FFR/iFR be deemed clinically inappropriate/unsafe to perform)

Secondary outcome measures

1. Patient-reported quality of life measured using the Seattle Angina Questionnaire (SAQ), Euroqol EQ-5D-5L, SF12v2 at 0, 6 and 12 months

2. Guideline-directed medical therapy (GDMT) usage measured using patient questionnaire results and/or GP records at 0, 6 and 12 months

3. Major Adverse Cardiovascular Events (all cause death, myocardial infarction [MI], unplanned percutaneous coronary intervention [PCI]/coronary artery bypass graft surgery [CABG]) measured using patient questionnaire results and/or GP records at 3 years

4. Resource use and cost efficiency measured using patient questionnaire results and/or GP records at 12 months

Overall study start date

30/05/2019

Completion date 26/04/2027

20/01/2021

Eligibility

Key inclusion criteria

1. Males \geq 45 years or females \geq 50 years

2. Atypical or typical angina

3. At least one major cardiac risk factor (diabetes, peripheral arterial disease, cerebrovascular disease, current or past tobacco use, hypertension, dyslipidaemia or family history of premature coronary artery disease)

4. Referred to NHS cardiology outpatient services

- 5. Requiring further investigation according to NICE CG95 guidelines
- 6. Deemed suitable for coronary revascularisation if required

Participant type(s)

Patient

Аде дгоир

Adult

Lower age limit 45 Years

Sex Both

Target number of participants

Planned Sample Size: 4000; UK Sample Size: 4000

Key exclusion criteria

In order to keep the trial generalisable to the UK population at large, only issues related to patient safety/appropriateness will form the exclusion criteria; these will include: 1. Prior normal CT coronary angiography (CTCA) within the last 2 years or prior CTCA with extensive calcification 2. Clinically unstable cardiac symptoms 3. Known coronary artery disease (including previous myocardial infarction [MI], acute coronary syndrome [ACS] or coronary revascularization)

4. Contraindication to CTCA or functional cardiac imaging

5. Pregnancy and/or breastfeeding

6. Known chronic renal failure (eGFR < 30ml/min/1.73m²)

7. Inability to give written informed consent

Date of first enrolment

27/04/2022

Date of final enrolment 08/08/2025

Locations

Countries of recruitment England

Scotland

United Kingdom

Study participating centre United Leeds Teaching Hospital NHS Trust Trust Hq Leeds General Infirmary Great George St Leeds United Kingdom LS1 3EX

Study participating centre Oxford University Hospitals

John Radcliffe Hospital Headley Way Headington Oxford United Kingdom OX3 9DU

Study participating centre Pinderfields Hospitals NHS Trust

Trust Hq, Rowan House Pinderfields General Hospital Aberford Road Wakefield United Kingdom WF1 4EE

Study participating centre Northumbria Healthcare NHS Foundation Trust North Tyneside General Hospital Rake Lane North Shields United Kingdom NE29 8NH

Study participating centre Harefield Hospital NHS Trust Harefield United Kingdom UB9 6JH

Study participating centre Royal Devon University Healthcare NHS Foundation Trust Royal Devon University NHS Ft Barrack Road Exeter United Kingdom EX2 5DW

Study participating centre South Tees Hospitals NHS Trust Middlesbrough General Hospital Ayresome Green Lane Middlesbrough United Kingdom TS5 5AZ

Study participating centre University Hospital Southampton NHS Foundation Trust Southampton General Hospital Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre Central Manchester University Hospitals NHS Foundation Trust Trust Headquarters, Cobbett House Manchester Royal Infirmary Oxford Road Manchester United Kingdom M13 9WL

Study participating centre Bradford Teaching Hospitals NHS Foundation Trust Bradford Royal Infirmary Duckworth Lane Bradford United Kingdom BD9 6RJ

Study participating centre

Nenedoc (kettering) Kettering General Hospital Rothwell Road Kettering United Kingdom NN16 8UZ

Study participating centre The Royal Wolverhampton NHS Trust New Cross Hospital Wolverhampton Road Heath Town Wolverhampton United Kingdom WV10 0QP

Study participating centre Norfolk & Norwich University Hospital Colney Lane Colney Norwich United Kingdom NR4 7UY

Study participating centre

Nottingham University Hospitals NHS Trust - City Campus Nottingham City Hospital Hucknall Road Nottingham United Kingdom NG5 1PB

Study participating centre NIHR Barts Clinical Research Facility 11th Floor Royal London Hospital Stepney Way London United Kingdom E1 1BB

Study participating centre Kings College Hospital

Mapother House De Crespigny Park Denmark Hill London United Kingdom SE5 8AB

Study participating centre Glenfield General Hospital Groby Road Leicester

United Kingdom LE3 9QP

Study participating centre The James Cook University Hospital Marton Road Middlesbrough United Kingdom TS4 3BW

Study participating centre

NIHR Barts Cardiovascular Biomedical Research Unit The Royal London Hospital Whitechapel London United Kingdom E1 1BB

Study participating centre North Bristol NHS Trust Southmead Hospital Southmead Road Westbury-on-trym Bristol United Kingdom BS10 5NB

Study participating centre Basildon University Hospital Nethermayne Basildon United Kingdom SS16 5NL

Study participating centre Queen Elizabeth University Hospital 1345 Govan Road Glasgow United Kingdom G51 4TF

Sponsor information

Organisation University of Leeds

Sponsor details

Faculty Research Office Room 9.29, Level 9, Worsley Building Leeds England United Kingdom LS2 9NL +44 (0)1133437587 governance-ethics@leeds.ac.uk

Sponsor type University/education

Website http://www.leeds.ac.uk/

ROR https://ror.org/024mrxd33

Funder(s)

Funder type Charity

Funder Name Heart Research UK; Grant Codes: TR2442/19/24

Alternative Name(s)

Funding Body Type Private sector organisation

Funding Body Subtype Other non-profit organizations

Location United Kingdom

Funder Name British Heart Foundation

Alternative Name(s) the_bhf, The British Heart Foundation, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location United Kingdom

Results and Publications

Publication and dissemination plan

A copy of the protocol will be available after publication. The researchers will work closely with the communications teams at Leeds Teaching Hospitals NHS Trust, University of Leeds and Heart Research UK to ensure that the findings are conveyed to the general public through mainstream broadcasters, press and patient groups, including online resources and social media (e.g. #NIHR@leeds). Findings will be presented at leading scientific conferences and in high-quality, high impact, peer-reviewed journals. Dissemination to patients will be supported through established national PPIE groups, in conjunction with the PPIE advisors involved with this trial. Lay summaries will be produced and published on the NIHR@Leeds websites, CTRU website, and Institute website. Dissemination will also take place through community engagement via research open days, Café Scientifique, and to other expert patient groups regionally and nationally, as guided by the patient advisors.

Intention to publish date

31/01/2028

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request (Prof. John Greenwood; P.Greenwood@Leeds.ac.uk) following the publication of the pre-specified primary and secondary endpoints. Data will be fully anonymised.

IPD sharing plan summary

Available on request

| Study outputs | | | | | | | | |
|--|-------------|--------------|--------------------------|----------------|-----------------|--|--|--|
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? | | | |
| Participant information sheet | version 1.0 | 16/08/2021 | 20/01/2022 | No | Yes | | | |
| HRA research summary Protocol article | | 13/06/2025 | 26/07/2023 18/07/2025 | No Yes | No No | | | |